U.S. Looks Bad in International COVID-19 Comparisons
The United States usually doesn’t fare very well in international health comparisons. The country’s healthcare ranks among, if not the, most expensive. The outcomes, as measured by metrics such as life expectancy at birth, are not top tier, especially when the U.S. is compared to well-off countries in Europe and Asia.
The United States usually doesn’t fare very well in international health comparisons. The country’s healthcare ranks among, if not the, most expensive. The outcomes, as measured by metrics such as life expectancy at birth, are not top tier, especially when the U.S. is compared to well-off countries in Europe and Asia.
The story with COVID-19 is similar, according to data reported recently by Kaiser Family Foundation. Among the dozen developed countries included in the foundation’s analysis, only Belgium, at 90.4 COVID-19-related deaths per 100,000 population, was worse than the U.S., at 66.5 COVID-19 deaths per 100,000. By contrast, Japan’s rate of 1.3 COVID-19 deaths per 100,000 is stunningly low, as is Australia’s (3.6 per 100,000) and Germany’s (11.7 per 100,000).
Kaiser’s ranking of the leading causes of death is also sobering. COVID-19 is on course to being the third leading cause of death in the U.S. in 2020, behind only the perennial leaders, heart disease and cancer. In Japan, COVID-19 is on track to being the 29th leading cause of death and in Germany, the 17th
In this latest episode of Tuning In to the C-Suite podcast, Briana Contreras, an editor with MHE had the pleasure of meeting Loren McCaghy, director of consulting, health and consumer engagement and product insight at Accenture, to discuss the organization's latest report on U.S. consumers switching healthcare providers and insurance payers.
Listen
A Renewed Commitment to HIV Vaccine Development Despite Advancements in Antiretrovirals | AIDS 2024
July 25th 2024The HIV vaccine field has recently faced setbacks with trials like PrepVacc, Mosaico and Imbokodo ending early due to lack of preventive efficacy. Although there have been challenges, scientists have made discoveries showing that the immune system can be prepared to fight HIV with special antibodies.
Read More
In our latest "Meet the Board" podcast episode, Managed Healthcare Executive Editors caught up with editorial advisory board member, Eric Hunter, CEO of CareOregon, to discuss a number of topics, one including the merger that never closed with SCAN Health Plan due to local opposition from Oregonians.
Listen
ViiV Healthcare Will Not Continue Trials of Subcutaneous Cabenuva | AIDS 2024
July 25th 2024A substudy of the FLAIR phase 3 trial found that participants favored intramuscular injection of Cabenuva over the subcutaneous version due to pain and the development of nodules and reddening of the skin.
Read More
